Cost of Revenue Comparison: CRISPR Therapeutics AG vs Evotec SE

A Decade of Cost Dynamics: CRISPR Therapeutics AG vs. Evotec SE

In the rapidly evolving biotech industry, understanding cost structures is crucial for investors and stakeholders. Over the past decade, CRISPR Therapeutics AG and Evotec SE have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, Evotec SE consistently outpaced CRISPR Therapeutics AG, with its cost of revenue peaking at approximately 606 million in 2023, a staggering 900% increase from 2014. In contrast, CRISPR Therapeutics AG saw a more modest rise, with its costs increasing by about 8600% over the same period, reaching around 130 million in 2023. This disparity highlights Evotec's aggressive expansion and operational scale compared to CRISPR's more measured growth. As the biotech landscape continues to shift, these cost trends offer valuable insights into each company's strategic priorities and market positioning.